tbuckley/cabot-search huggingface dataset:
The Genotype in the Donor and Recipient for the Polymorphim −174 G/C of the IL-6 Influences the Outcome of HLA-Identical Related Stem Cell Transplantation,
Authors: Carolina Martinez-Laperche, Victor Noriega, Adela Herraiz, A. Bosh, Beatriz Martin-Antonio, V. Guillem, Jose B Nieto, Marcos González, Rafael Camara De La, S. Brunet, Antonio Jimenez-Velasco, Ildefonso Espigado, Juan Carlos Vallejo Llamas, Antonia Sampol, Alvaro Urbano-Ispizua, David Serrano, Jorge Gayoso, Pascual Balsalobre, Carlos Solano, David Gallardo, Jose Diez-Martin, Ismael Buno
Journal: Blood (2011)
Recurrence and Mesh-Related Complications After Incisional Hernia Repair
Authors: Deepa Cherla, William Hope, Mike K. Liang
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DDIS-08. DRUG REPOSITIONING TARGETING GLIOMA STEM CELLS
Authors: Mitsutoshi Nakada, Yu Dong, Tomohiro Kitabayashi, Hemragul Sabit, Takuya Furuta, Atsushi Hirao
Journal: Neuro-Oncology (2016)

Drug repositioning refers to the discovery of new indications for approved or failed drugs and the application of the newly identified drugs to the management of diseases other than the drug’s intended disease. It reduces the risk of developmental failure, cost, and time of development. Malignant gliomas have only limited therapeutic options, because of highly tumorigenic subpopulations of glioma stem cells (GSCs). Therefore, therapies targeting GSCs are of ultimate importance, since they may be able to decrease recurrence. Here, we tried to identify existing drugs which suppress glioma stem cells. At the first screening, drug screening Libraries (total 1,301 drugs) used for this study were: FDA-approved drug library (ENZO; CB-BML-2841J0100), ICCB known bioactives library (ENZO; CB-BML 2840J0100), kinase inhibitor library (ENZO; CB-BML-2832J0100), fatty acid library (ENZO; CB-BML-2803J0100) and phosphatase inhibitor library (ENZO; CB-BML-2834J0100). To confirm the effects of individual compounds, glioma stem cells were treated with a compound at three doses in 384-well plates, followed by analysis of cell viability with WST assay. The second screening was exclusion of drugs which have been already reported. At the third screening, WST assay and neurosphere assay were performed for glioma stem cells with low concentration of candidate drugs. Subsequently, invasion and proliferation assays were performed with glioma cell lines (U87, U251, T98G, SNB19) treated by candidate drugs. Mouse glioma model made by transplantation of glioma stem cells were treated by candidate drugs. From our first, second, third screening, we selected 89, 36, 3 drugs, respectively. Then, we focused one drug and could confirm the inhibitory effect of proliferation and invasion both in vitro and in vivo. Taken together, we identified existing drugs which suppress glioma stem cells. We are now planning a clinical study.
Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies
Authors: Aurelie Cabannes-Hamy, Frederic Peyrade, Fabrice Jardin, Jean-Francois Emile, Sylvie Castaigne, Bertrand Coiffier, Corinne Haioun, Aurore Perrot, Olivier Fitoussi, Safia Chebrek, Christophe Fruchart, Julie Abraham, Richard Delarue, Marc Andre, Gilles Salles, Philippe Gaulard, Herve Tilly, Catherine Thieblemont
Journal: Blood (2016)
Four hour target for emergency departments isn’t clinically sound
Authors: M Justin Zaman
Journal: BMJ (2017)

The statistics that track its performance might be part of the NHS’s problem.12 The idea that 95% of patients attending hospital emergency departments should be seen and admitted or discharged in four hours was wrong from the start. Lay friends ask me whether triage still works effectively; the sickest do get seen first, but the four hour limit means that patients do not feel …
Hypertension—A Global Neurological Problem
Authors: Jerome H. Chin, Jaydeep M. Bhatt, Alexandra J. Lloyd-Smith
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Comparison of Clinical Diagnosis for Hereditary Spherocytosis with Molecular Diagnosis By Multi-Gene Target Sequencing in Korea
Authors: Hyoung Soo Choi, Qute Choi, Jung Ah Kim, Kyong Ok Im, Si Nae Park, Yoomi Park, Ju Han Kim, Hee Young Shin, Seon Young Kim, Hyoung Jin Kang, Hoon Kook, Soo-Jeong Kim, Inho Kim, Ji Yoon Kim, Hawk Kim, Kyung Duk Park, Kyung Bae Park, Meerim Park, Sang Kyu Park, Eun Sil Park, Jeong-A Park, Ji Kyoung Park, Hee Jo Baek, Jeong Ho Seo, Ye Jee Shim, Hyo Seop Ahn, Keon Hee Yoo, Hoi Soo Yoon, Kun Soo Lee, Kwang Chul Lee, Jae Min Lee, Mee Jeong Lee, Sun Ah Lee, Jun Ah Lee, Jae Hee Lee, Ji Won Lee, Young-Woong Won, Young Tak Lim, Hyun Joo Jung, Hee Won Cheuh, Eun Jin Choi, Hye Lim Jung, Dong Soon Lee, The Hereditary Hemolytic Anemia Working Party of the Korean Society of Hematology
Journal: Blood (2016)
NIMG-65. IN VIVO DETECTION OF 2-HYDROXYGLUTARATE IN LOW-GRADE IDH-MUTANT GLIOMAS WITH STABLE DISEASE
Authors: Yan Li, Janine Lupo, Susan Chang, Sarah Nelson
Journal: Neuro-Oncology (2016)

The accumulation of 2-hydroxyglutarte (2HG) that is associated with isocitrate dehydrogenase (IDH) mutations can be non-invasively detected using MRS, with sequences such as asymmetric and 2HG-edited PRESS. Nine patients with grade 2 IDH-mutant glioma (5 oligodendroglioma and 4 astrocytoma) were studied 2-38 months after surgery and were clinically stable. Three patients were followed every 2 months, with 1 patient having 4, 1 having 3 and 1 having 2 MR exams, respectively, for a total of 15 exams. A single voxel MRS prescription was placed to cover the majority of the T2-hyperintense-lesion. Both asymmetric and 2HG-edited PRESS were acquired with voxel size of 2x2x2cm3 and acquisition time of 4.5min. Due to limitations on total scan time, 12 asymmetric and 15 edited spectral datasets were obtained. 2HG was unambiguously identified in only 2 of the 12 asymmetric datasets (16.7%) and these were both from the patient who had 4 MR scans. The correlation coefficients between detecting 2HG and levels of Cho/Cr and Cho/NAA were 0.65 and 0.52, respectively. Although the edited PRESS acquisition improved detection of 2HG compared to the asymmetric PRESS, 2HG, it was still only detected in 40% of the relevant exams (6/15). The overall low detection rates of 2HG may be due to overlap with GABA, to the relatively broad linewidth of the peak for the asymmetric sequences, to the contamination of residual water for the editing sequence or the fact that these patients were clinically stable and have limited tumor. Serial assessment of more patients who are being followed during the course of progression would help to elucidate whether the low 2HG levels observed are due to the disease status or lack of sensitivity of the techniques. Understanding the evolution of 2HG production over time is important for monitoring the effectiveness of therapy in future clinical trials.
Partner’s survivorship care needs: Multivariable analysis in head and neck cancer patients.
Authors: Meredith Elana Giuliani, Maurene McQuestion, Lorna Sampson, Lisa W Le, Jennifer M. Jones, Terry Cheng, John N. Waldron, Jolie Ringash
Journal: Journal of Clinical Oncology (2016)

120 Background: The purpose of this study was to determine the number and predictors of head and neck cancer (HNC) survivors’ partners unmet needs and how they correspond to the unmet needs of the survivor. Methods: This study accrued consenting partners from among 158 patients with HNC who had completed a onetime survey including demographic information and the Cancer Survivors’ Unmet Needs Measure (CaSUN) between January 2013 and May 2014. Patients’ caregivers were invited to complete the Cancer Survivors’ Partners Unmet Needs Survey (CaSPUN). The mean (± standard deviation) number and proportion of unmet needs on the CaSPUN was calculated. Multivariable analyses (MVA) were performed to determine factors associated with greater unmet needs using linear regression. Kappa co-efficient was calculated to examine the agreement between the unmet needs of patients and their partners on 22 corresponding items. Results: The CaSPUN survey was completed by 44 partners of head and neck cancer survivors. At least one unmet need was reported by 29 partners and 4 had a very high number of needs between 31 and 35. The most common unmet needs were “I need help to manage my concerns about the cancer coming back” (41%), “I need more accessible hospital parking” (34%), “ I need help to cope with others not acknowledging the impact of having a partner experience cancer has had on my own life” (30%), “ I need help dealing with changes that cancer has caused in my partner” (27%) and “I need to know all my partners doctors talk to each other to coordinate my partner’s care” (27%). Of the 5 most common items, 3 were in the Relationships domain. On MVA increasing number of unmet needs in patients was significantly associated with increased unmet needs in their partners (p &lt; 0.01). Of the 22 paired items there was fair agreement in 12 items, moderate agreement in 8 items and good agreement in 2 items between patients and partners. Conclusions: A significant proportion of partners of cancer patients experience unmet needs which may differ from those of the patient themselves. Survivorship program should consider independent needs assessment and program development for partners.
483TiP A Phase (Ph) III clinical program: 1L atezolizumab (atezo) plus chemotherapy (chemo) in chemo-naive advanced NSCLC
Authors: T.S.K. Mok, R.M. Jotte, F. Cappuzzo, M. Reck, V. Papadimitrakopoulou, H.J. West, A. Sandler, S. Mocci, S. Coleman, T. Asakawa, M.A. Socinski
Journal: Annals of Oncology (2016)
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
Authors: R. Hui, E.B. Garon, J.W. Goldman, N.B. Leighl, M.D. Hellmann, A. Patnaik, L. Gandhi, J.P. Eder, M.-J. Ahn, L. Horn, E. Felip, E. Carcereny, R. Rangwala, G.M. Lubiniecki, J. Zhang, K. Emancipator, C. Roach, N.A. Rizvi
Journal: Annals of Oncology (2017)

BackgroundPembrolizumab improved survival as first- and second-line therapy compared with chemotherapy in patients with highly programmed death ligand 1 (PD-L1) expressing advanced non-small cell lung cancer (NSCLC). We report the long-term safety and clinical activity of pembrolizumab as first-line therapy for patients with advanced NSCLC and the correlation between PD-L1 expression and efficacy.Patients and methodsIn the open-label phase 1b KEYNOTE-001 trial, treatment-naive patients with advanced NSCLC whose tumors expressed PD-L1 (≥1% staining, assessed using a prototype assay) were randomly assigned to intravenous pembrolizumab 2 or 10 mg/kg every 3 (Q3W) or 2 (Q2W) weeks. Response was assessed per central RECIST v1.1 every 9 weeks in all patients who received ≥1 pembrolizumab dose. Using pre-treatment tumor tissue, a clinical assay quantified the percentage of tumor cells expressing PD-L1 as tumor proportion score (TPS).ResultsBetween 1 March 2013 and 18 September 2015, 101 patients received pembrolizumab 2 mg/kg Q3W (n = 6), 10 mg/kg Q3W (n = 49), or 10 mg/kg Q2W (n = 46). Of these, 27 (26.7%) had TPS ≥50%, 52 (51.5%) had TPS 1%–49%, and 12 (11.9%) had TPS <1%. The objective response rate (ORR) was 27% (27/101, 95% CI 18–37) and median overall survival was 22.1 months (95% CI 17.1–27.2). In patients with PD-L1 TPS ≥50%, ORR, 12-month PFS, and 12-month OS were higher [14/27 (51.9%; 95% CI 32%–71%), 54%, and 85%, respectively] than the overall population [27/101 (26.7%; 95% CI 18.4%–36.5%), 35%, 71%]. Pembrolizumab was well tolerated, with only 12 (11.9%) patients experiencing grade 3/4 treatment-related adverse events and no treatment-related deaths.ConclusionsPembrolizumab provides promising long-term OS benefit with a manageable safety profile for PD-L1-expressing treatment-naive advanced NSCLC, with greatest efficacy observed in patients with TPS ≥50%.Clinical trial name and numberKEYNOTE-001 (ClinicalTrials.gov, NCT01295827).
Randomized Double-Blind Controlled Trial of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Authors: Alex J. Mackay, Anant R. C. Patel, Richa Singh, Raymond J. Sapsford, Gavin C. Donaldson, Niyati Prasad, Udo-Michael Goehring, Tsz Keung Nip, Jadwiga A. Wedzicha
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
8P Cdk4/6 inhibitor activity in metastatic bladder cancer cell lines is independently of RB1 status
Authors: D. Castellano, C. Rubio, F. Lopez-Calderon, C. Segovia, M. Duenas, M. Martinez-Fernandez, I. Otero, R. Manneh, G. De Velasco, J. Paramio
Journal: Annals of Oncology (2016)
Reduced Intensity Conditioning (RIC) with Rituximab Yields Excellent Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed Follicuar Lymphoma (FL): A Phase II Multicenter Trial from the Blood and Marrow Transplant Network (BMT CTN 0701)
Authors: Ginna G. Laport, Juan Wu, Brent R. Logan, Veronika Bachanova, Chitra M. Hosing, Timothy S. Fenske, Walter L. Longo, Steven M. Devine, Auayporn P. Nademanee, Iris Gersten, Mary M. Horowitz, Hillard M. Lazarus, Marcie L Riches
Journal: Blood (2014)
Moving forward after cancer: Implementation of transition appointments and follow-up care plans in Manitoba.
Authors: Tara Carpenter-Kellett, Jeffrey James Sisler
Journal: Journal of Clinical Oncology (2016)

50 Background: Patient experience and local and international clinical research have focused attention on transitions in cancer care from treatment to follow-up. Deficiencies in the quality of survivorship care, including necessary testing, have been demonstrated. The Canadian Partnership Against Cancer has funded projects designed to enhance the implementation of survivorship care plans (SCPs) and to improve cancer system-primary care coordination. CancerCare Manitoba, a provincial agency, is a leader in this work. Methods: The Moving Forward After Cancer initiative combines the generation of standardized written SCPs from the EMR with enhanced patient assessment at the end of curative systemic / radiation therapy. A transition appointment (TA) is provided by the patient’s usual oncology providers and includes screening for distress, appropriate referrals, and provision of a personalized treatment summary and SCP to the patient, with copies to the primary care physician and surgeon. The TA often marks the transfer of medical responsibility to the primary care provider (PCP). Results: Transition appointments have been implemented for colorectal (2012), breast (2014), and lymphoma and gynecologic cancer patients (2015). A total of 364 TAs were done in Manitoba in 2014, of which 140 were with colorectal (stage II and III) and 224 with breast (stage I – III) patients, about 59% and 35% respectively of eligible patients. This is an increase of 385% from the 75 TAs done in 2013. Other patient outcomes being collected include perceptions of continuity of care, confidence in survivorship information, evaluation of the care plan documents and also PCP and oncology team perceptions. In order to support practice change, a workflow solution led by a designated team that is adaptable by all sites across the province has been developed. Conclusions: The provision of TAs and SCPs is being well adopted in Manitoba. We expect that this intervention willimprove the experience of both patients and health care providers and the quality of care at the time of transition to survivorship. Implementation is underway with other disease site groups with the goal of all patients receiving a TA as they transition into survivorship.
Role of Bcl-2 Immunohistochemical Expression As An Independent Biological Prognostic Marker At Diagnosis of Classical Hodgkin's Lymphoma
Authors: Leyre Bento, Gabriela Rodriguez Macias, Pascual Balsalobre, Jorge Gayoso, Isabel Gonzalez-Gascon y Marin, Cristina Muñoz-Martínez, Mi Kwon, David Serrano, Javier Menárguez, Jose Luis Diez Martin
Journal: Blood (2011)
Prevalence of Allergic Rhinitis, Atopic Dermatitis and Asthma among school children in Hyderabad, India
Authors: Vaishnavi Veerapaneni, Jayaraj BS, Lokesh KS, Chaya SK, Vishnun rao Veerapaneni, Amrutha Holla, Mahesh Pa
Journal: Journal of Allergy and Clinical Immunology (2017)
Real Life Efficacy and Safety of Rivaroxaban for Extended VTE Treatment – First Results of the Prospective Noac Registry (NCT01588119).
Authors: Christina Koehler, Sebastian Werth, Vera Gelbricht, Ulrike Haensel, Luise Tittl, Ines Beyer-Westendorf, Thomas Schreier, Maria Eulitz, Jan Beyer-Westendorf
Journal: Blood (2012)
Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B
Authors: Paola Fisicaro, Valeria Barili, Barbara Montanini, Greta Acerbi, Manuela Ferracin, Francesca Guerrieri, Debora Salerno, Carolina Boni, Marco Massari, M Cristina Cavallo, Glenda Grossi, Tiziana Giuberti, Pietro Lampertico, Gabriele Missale, Massimo Levrero, Simone Ottonello, Carlo Ferrari
Journal: Nature Medicine (2017)
Estkus in Virgin Strain C3H (High-Tumor) and Virgin Strain A (Low-Tumor) Mice and in the Reciprocal (A × C3H) F1 Hybrids
Authors: Margaret K. Deringer, Walter E. Heston, Howard B. Andervont
Journal: JNCI Journal of the National Cancer Institute (1945)

Journal Article Estkus in Virgin Strain C3H (High-Tumor) and Virgin Strain A (Low-Tumor) Mice and in the Reciprocal (A × C3H) F1 Hybrids Get access Margaret K. Deringer, Margaret K. Deringer Search for other works by this author on: Oxford Academic PubMed Google Scholar Walter E. Heston, Walter E. Heston Search for other works by this author on: Oxford Academic PubMed Google Scholar Howard B. Andervont Howard B. Andervont Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 5, Issue 6, June 1945, Pages 403–405, https://doi.org/10.1093/jnci/5.6.403 Published: 01 June 1945
Quality of life difficulties in partners of young breast cancer survivors.
Authors: Victoria Champion, Andrea A Cohee, Patrick Monahan, Timothy E. Stump, Kathy Miller, Lynne Wagner, David Cella, George Sledge
Journal: Journal of Clinical Oncology (2016)

188 Background: Although breast cancer is more commonly diagnosed in post-menopausal women, there are a significant number of survivors diagnosed at age 45 or younger. Compared to older survivors, younger survivors have significantly more problems with depression sexual functioning, marital satisfaction, and overall well-being, but there is little research on the partners of these younger survivors. The purpose of this study is to determine if the partners of young survivors experience more problems with depression, sexual functioning, marital satisfaction, and overall well-being than partners of age-matched controls. Methods: Survivors and partners (n=227) were enrolled in a large cross-sectional study, executed through the ECOG-ACRIN Cancer Research Group. Eligibility for survivors included being 45 or under at diagnosis, 3 to 8 years from treatment without a breast cancer recurrence, and with similar chemotherapy treatment regimens. Survivors identified age-matched acquaintance controls without breast cancer. These age matched controls and their partners (n=170) were also included. All groups completed a survey assessing demographic characteristics, depression, sexual functioning (enjoyment and difficulty), marital satisfaction, and overall well-being. The partners of both young survivors and acquaintance controls were compared on all study variables adjusting for demographic variables. Results: Partners of young survivors reported significantly more depression (effect size [ES] = -0.23, p=.0199), worse sexual functioning as indicated by lower enjoyment (ES= 0.32, p=.0019) and more sexual difficulty (ES= -0.24, p=.0164), lower marital satisfaction (ES=0.24, p=.0189), and lower overall well-being (ES= 0.40, p=.0001). Conclusions: Partners of breast cancer survivors suffer from problems similar to breast cancer survivors. Further research is needed to fully understand the impact of a breast cancer diagnosis on both the partner as well as the survivor, especially when problems exist that are related to the dyadic relationship.